News

30.01.2012
European Patent Office intends to grant Sangui wound dressing patent

Witten, Germany, January 30, 2012 - The European Patent Office has officially expressed its intention to grant a patent based on Sangui's application "Therapeutically Active Wound Dressings, Production thereof, and Use of the same". The publication of the grant is only subject to Sangui filing the requested additional translations into other official European languages. These translations are currently under way. The projected duration of the patent will not expire prior to 2024.

Wound dressings serve to safeguard the wound with its highly sensitive new granulation tissue from mechanical damage as well as from infection. Using the natural polymer chitosan derived from crab shells, Sangui's Chitoskin wound dressings show outstanding properties in supporting wound healing. The Chitoskin wound dressing shows excellent results in securing a moist wound climate while stimulating cell growth and serving as a cell matrix. Being the only foam based on natural, organic raw material it also has antibacterial properties.

25.01.2012
European Patent Office intends to grant Sangui key oxygen carrier patent

Witten, Germany, January 25, 2012 - The European Patent Office has officially expressed its intention to grant a patent based on Sangui's application (01 945 245) "Mammalian hemoglobin compatible with blood plasma, cross-linked and conjugated with polyalkylene oxides as artificial medical oxygen carriers, production and use thereof". The publication of the grant is only subject to Sangui filing the requested additional translations into other official European languages. These translations are currently being carried out. The projected duration of the patent will not expire prior to 2020. There is an option to have the duration extended for another five years. Sangui already holds a granted US patent on the basis of the same application

The process protected by this patent is one of the cornerstones of Sangui's concept of artificial oxygen carriers. The so called pegylation (coating with polyethylene glycol) of the hemoglobin hyperpolymers serves several purposes, most important of which are a reduced immune reaction as well as minimized extravasations, increasing the intravascular persistence of the carrier in the blood and reducing a pharmacological vasoconstriction.

Key properties of artificial oxygen carriers include life saving oxygen supply to the heart or brain in cases of heart attack or stroke. As compared to other means of induced oxygen transport, Sangui's artificial oxygen carriers are expected to have additional advantages: simple storage, long shelf-life, they are blood group independent, free from infectious agents (viruses), and will be permanently available in sufficient quantities.

12.12.2011
Mexican State of Tamaulipas starts training doctors in Sangui wound management

Sangui enters commercialization phase / Initial order of Sangui developed wound spray

Witten, Germany, December 12, 2011

The Mexican State of Tamaulipas has issued an initial order of Hemo2Spray, the Sangui developed wound spray, as well as of the wound debridement product Scabremove both registered by the Mexican authorities in September this year. This is the first regular commercial order of the wound spray and Sangui management is positive that an era of innovative product development, testing and authorization will now come to fruition.

The medical product will initially be used in three state owned hospitals. While it will serve to treat patients suffering from chronic wounds its use in actual treatments will particularly be part of a comprehensive training program for doctors from other locations in Tamaulipas. The State health authorities have expressed their intent to apply the Sangui developed wound therapy in the 22 hospitals under their direction and start now in cooperation with Sangui medical staff to instruct and train their medical personnel. Global licensee SastoMed GmbH which is in charge of wound management operations expects that demand for the product will ramp up quickly when experienced doctors start treating patients throughout the state and as other Mexican states follow suit. Invoicing is to occur at short notice while shipment of the product is scheduled for early January 2012.

19.09.2011
Mexico authorizes use of Sangui developed wound management system

Official registration as medical device granted / State of Tamaulipas indicates plans to start treatment in 22 hospitals

Witten, Germany, September 19, 2011

The Mexican Commission for the Authorization of Pharmaceuticals and Medical Devices officially registered the entire current range of Sangui developed wound management products as medical devices and granted permission to use this treatment on a nationwide basis.

In the meantime the Secretaria de Salud (Secretary of Health) of the Mexican State of Tamaulipas as a first legal entity in Mexico indicated in an official letter that it has the firm intention to actually apply the Sangui developed wound therapy in the 22 hospitals under its direction. It is to be recommended as the state of the art treatment of chronic wounds in the indications of leg ulcer and diabetic foot. An exact starting date for this program has not been fixed yet. SanguiBioTech GmbH and SastoMed GmbH as global licensee are ready to jointly enter negotiations about the terms of trade with customers in Mexico and beyond. It is being assumed that the official registration in Mexico may serve as a door opener for respective registrations in other Central American countries.

This is the first official authorization to use and distribute the Sangui developed wound treatment. Comprehensive clinical test treatments had been carried out in 2009 at the Hospital Civil in Ciudad Victoria, capital of the Mexican state of Tamaulipas. The tests were concluded successfully. In the course of the treatments the control group had been closed and patients shifted to the Sangui developed therapy for ethical reasons. In the event the total healing ratio was significantly higher than 75%.

The results were evaluated by the State Health Authorities of Tamaulipas and presented to the Mexican Federal Health Authorities as well as on the occasion of international dermatological and wound management congresses. The certification process in compliance with Mexican and international standards was carried out professionally by the staff and consultants of Sangui Latin America SA, the legally non-related local partners of Sangui BioTech International, Inc. in Mexico.

Eduardo Martinez Mena, CEO of Sangui Latin America SA, emphasized: "In close cooperation with our German partners we invested a considerable amount of time, money and diligence in this project over the past five years. We are more than glad that our continued efforts now have come to fruition and very excited about the huge opportunities this authorization will offer for the patients as well as for our company."

Sangui BioTech International, Inc., Director Hubertus Schmelz congratulated: "Our Mexican partners have attained the first manifest breakthrough for our products - and hence for Sangui as a whole. The Mexican authorization is the seal and first official confirmation of their therapeutic properties, and is the logic result of the studies conducted by the Tamaulipas Health Authorities. The certification processes worldwide are designed to protect the patients and, therefore, extensive, detailed and time consuming. But this event now shows that our joint professional and diligent approach is the right and only way to reach our business objectives."

Michael Sander, Managing Director of SastoMed, explained: "We are proud to find that the Mexican authorities are leading the way to give patients access to our novel and promising treatment of chronic wounds. To a considerable extent, the smooth registration process in Mexico was due to the comprehensive work we carried out to gain convincing data to prove the safeness and efficacy of the treatment. As authorities' demands regarding medical devices are broadly comparable we confirm our ambitious schedule towards an EU registration as the next step to a global market entry."

All parties agreed that their cooperation over the years has proved to be successful, resting solidly on their common trust in the properties of this unique wound healing therapy. Both SastoMed and Sangui underlined that the German side is ready to enter negotiations about terms and deliveries and is currently initiating the necessary preparations to have the products manufactured in the required qualities and quantities.

Mexican health authorities lay special emphasis on their continued efforts to abate the consequences of lifestyle diseases such as diabetes. Estimates indicate that more than 40% of the Mexican population suffers from venous diseases. Currently, there are 17 million identified diabetics in Mexico, this being the second largest diabetes rate in the world. In Mexico more than $30 bn per year are being spent on diabetics' treatments. It is being expected that the consistent use of the Sangui developed wound treatment will help to significantly reduce the costs in this particular sector.

20.12.2010
SanguiBioTech and SanderStrothmann Establish Joint Venture
Sangui Sells Hemospray Marketing and Sales License to New Company

Witten, Germany, December 20, 2010 SanguiBioTech GmbH, Witten, Germany, and SanderStrothmann GmbH, Georgsmarienhuette, Germany, have established a joint venture company under the name of sastOmed GmbH. The respective agreements and articles were now signed, and recorded by a notary.

It is the purpose of the new company to obtain the CE mark certification of the Hemospray wound spray and to start producing, marketing and distributing the product on a global scale. To this effect, Sangui has granted sastOmed GmbH comprehensive and exclusive licenses on a global scale. Project management, financing and execution of the projected activities will be taken care of by the joint venture which will be headed by Michael Sander and Rene Strothmann, Managing Directors of SanderStrothmann GmbH, who in addition will contribute their experience in product development and their proven industry contacts and cooperations.

Under the terms of the contracts sastOmed will pay a milestone-based downpayment as compensation for the licenses and has granted Sangui royalties on all future sales of the product. The parties agreed not to disclose any further details of the agreements and articles.

Hubertus Schmelz, Managing Director of SanguiBioTech GmbH emphasized: "Since 2004, it was one of our key strategic goals to cooperate with an industry partner with the financial and operating power and expertise to successfully develop, promote, and market our key products. The joint venture and licensing agreement is a decisive breakthrough on our way to reaching our goals." SanguiBioTech GmbH will now be in the position to focus on its other cosmetics and wound management products as well as on long term projects such as the artificial oxygen carrier.

Find more information here.

Our latest News is published through Sangui BioTech Int., Inc., the holding company. Please follow this link.